DCT

2:26-cv-11870

Takeda Pharmaceutical Co Ltd v. Sun Pharmaceutical Industries Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-11870, D.N.J., 09/11/2026
  • Venue Allegations: Plaintiff Takeda alleges that venue is proper in the District of New Jersey because Defendant Sun conducts business in the district, derives substantial revenue from sales there, and will likely market its accused generic product in the state. The complaint further notes that Sun has previously consented to jurisdiction in the District of New Jersey in other patent cases.
  • Core Dispute: Plaintiff alleges that Defendant’s filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff’s antiviral drug LIVTENCITY® (maribavir) constitutes an act of infringement of a patent covering specific methods of using the drug.
  • Technical Context: The technology relates to pharmaceutical methods for administering the antiviral compound maribavir to treat cytomegalovirus (CMV) infections, particularly methods designed to avoid a loss of efficacy due to in-vivo isomerization of the drug.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Defendant's submission of ANDA No. 219690 with a Paragraph IV Certification, asserting that its proposed generic product does not infringe or that the patent-in-suit is invalid. The patent-in-suit is listed in the FDA's Orange Book for LIVTENCITY®. The complaint alleges Defendant provided notice of its ANDA filing via a letter dated July 29, 2026.

Case Timeline

Date Event
2010-10-28 '368 Patent Priority Date
2026-06-23 '368 Patent Issue Date
2026-07-29 Defendant's Purported Notice Letter
2026-09-11 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,661,368 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

The Invention Explained

  • Problem Addressed: The patent's background describes the "unexpected discovery that maribavir may isomerize under in vivo conditions," meaning it can change into different molecular structures after being administered to a patient '368 Patent, col. 2:65-67 This isomerization can result in "less effective compounds," thereby reducing the drug's bioavailable concentration and overall therapeutic efficacy '368 Patent, col. 2:17-24 The patent links this phenomenon to the failure of a prior Phase 3 clinical study for maribavir, which, unlike an earlier successful study, allowed dosing under "fed conditions" '368 Patent, col. 2:50-59
  • The Patented Solution: The invention claims specific methods for administering maribavir that are designed to enhance its efficacy and mitigate the negative effects of isomerization '368 Patent, col. 1:30-34 The core of the patented solution is a defined dosing regimen, specifically "orally administering... 400 mg twice a day" using an "immediate release formulation" that dissolves in less than 60 minutes '368 Patent, claim 1 The specification suggests that controlling administration conditions, such as using "fasted conditions," can reduce isomerization and enhance bioavailability '368 Patent, col. 3:10-13 '368 Patent, col. 5:8-11
  • Technical Importance: The claimed methods provided a potential solution to rescue a clinically promising antiviral drug that had encountered a significant, and previously unrecognized, pharmacokinetic hurdle during its late-stage development '368 Patent, col. 2:27-32

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims" of the '368 patent without specifying them Compl. ¶28 The patent contains two independent method claims. Claim 1 is representative.
  • The essential elements of independent Claim 1 are:
    • A method of treating a cytomegalovirus (CMV) infection in a patient with a CMV infection.
    • The method comprises orally administering the compound maribavir in an amount of 400 mg twice a day.
    • The compound is administered as a composition in a therapeutically acceptable medium.
    • The composition is an "immediate release formulation."
    • The immediate release formulation releases the compound by dissolution in less than 60 minutes.
  • The complaint does not explicitly reserve the right to assert dependent claims, as there are none in the '368 Patent.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Sun's ANDA Product," identified as maribavir tablets, 200 mg, for which Defendant Sun has sought FDA approval via ANDA No. 219690 Compl. ¶22

Functionality and Market Context

The complaint alleges that Sun's ANDA Product is intended to be a generic version of Takeda's LIVTENCITY® drug Compl. ¶26 LIVTENCITY® is a cytomegalovirus (CMV) pUL97 kinase inhibitor used for treating post-transplant CMV infection in certain patient populations Compl. ¶5 The infringement action is premised on the act of submitting the ANDA, which seeks approval to manufacture and sell this generic version prior to the expiration of the '368 patent Compl. ¶28 The complaint alleges that the FDA-approved labeling for LIVTENCITY® "instructs and encourages" administration according to the methods claimed in the '368 patent, implying that Sun's proposed generic label will do the same Compl. ¶8 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not include a claim chart. The infringement theory is based on 35 U.S.C. § 271(e)(2), where the submission of an ANDA for a drug claimed in a patent is an act of infringement. The following table summarizes the likely infringement allegations for Claim 1 based on the complaint's assertions.

'368 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating a cytomegalovirus (CMV) infection in a patient having a CMV infection... Sun's ANDA product is a generic version of LIVTENCITY®, which is indicated for treating post-transplant CMV infection. ¶5; ¶26 col. 1:40-44
...comprising orally administering to the patient the compound [maribavir] in an amount of 400 mg twice a day... The complaint alleges Sun's ANDA is for 200 mg tablets and that the FDA-approved labeling for the reference drug, LIVTENCITY®, instructs administration according to the claimed methods. ¶8; ¶22 col. 8:1-4
...wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium... Sun's ANDA seeks approval for a pharmaceutical tablet formulation. ¶22 col. 8:5-8
...wherein said composition is an immediate release formulation... The complaint does not provide sufficient detail for analysis of this element, though it is implied by the allegation that Sun's product is a generic equivalent of LIVTENCITY® and that its label will encourage infringing use. ¶8; ¶26 col. 6:30-34
...and wherein the immediate release formulation releases said compound from said formulation by dissolution in less than 60 minutes. The complaint does not provide sufficient detail for analysis of this element, as it is a technical definition of the formulation's performance. ¶8; ¶26 col. 8:9-12
  • Identified Points of Contention:
    • Scope Questions: The core question in this Hatch-Waxman case is whether the instructions for use in the proposed label for Sun's generic product will direct or encourage physicians and patients to administer the drug in a manner that falls within the scope of the '368 patent's method claims. Specifically, will the label instruct a 400 mg twice-daily dose for the treatment of an active CMV infection?
    • Technical Questions: A key technical question, which may require discovery into the specifics of Sun's ANDA, is whether Sun’s formulation is, in fact, an "immediate release formulation" that meets the claim's functional requirement of releasing the drug via dissolution in less than 60 minutes.

V. Key Claim Terms for Construction

  • The Term: "immediate release formulation"
  • Context and Importance: This term is central to the claimed solution. The patent distinguishes its claimed method from prior art dosing protocols in part by specifying the formulation type. The interpretation of this term will be critical to determining if Sun's ANDA product, and the method of using it, falls within the claim scope.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party might argue the term should be given its plain and ordinary meaning as understood by a person of ordinary skill in the art of pharmaceutical formulation, potentially independent of the subsequent functional definition in the claim.
    • Evidence for a Narrower Interpretation: The patentee will almost certainly argue that the claim itself provides an explicit definition. Claim 1 recites "...wherein the immediate release formulation releases said compound... by dissolution in less than 60 minutes." The specification reinforces this with a clear statement: "The term 'immediate release' is defined to mean release of drug from drug formulation by dissolution is less than 60 minutes..." '368 Patent, col. 6:30-34 This provides strong evidence that the term was intended to be limited by this specific functional definition.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement allegation is based on the assertion that Sun's product label will instruct and encourage users to perform the patented method, and that Sun has knowledge of the patent since at least the date of its Paragraph IV certification Compl. ¶31 Compl. ¶33 The contributory infringement claim alleges that Sun's ANDA product is especially adapted for the infringing use and has no substantial non-infringing use Compl. ¶32
  • Willful Infringement: The complaint does not use the word "willful." However, it alleges that the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285 Compl. ¶35 Compl. Prayer J The basis for this is not detailed but is implicitly tied to Sun's alleged knowledge of the patent and its decision to seek approval for its generic product Compl. ¶33

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement: will the final, FDA-approved label for Sun’s generic product inevitably lead some users to practice the patented method by instructing a 400 mg twice-daily oral dose using an immediate-release formulation for the treatment of active CMV infection?
  • A second key question will be one of claim construction and technical fact: what is the proper construction of "immediate release formulation," and does Sun's ANDA product meet the functional requirement of releasing the drug "by dissolution in less than 60 minutes" as explicitly defined and required by the patent's claim language?